Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 50 Life Science Startup Investors in United States in July 2025

Last updated: Jul 2025 A list of 50 angel investors and VC (Venture Capital) funds that invest in Life science startups based in United states. We rank investors based on the number of investments they made in Life science companies from United states. We update this investor list every month.

Top 50 Life Science Startup Investors in United States in July 2025

Investor	Life Science United States investments
ARCH Venture Partners	24
SOSV	21
Alexandria Venture Investments	20
Northpond Ventures	19
RA Capital Management	15
Novartis Venture Fund	14
Third Rock Ventures	13
Atlas Venture	13
8VC	12
DCVC	12
Civilization Ventures	12
Alix Ventures	12
Fifty Years	11
Hatteras Venture Partners	11
OrbiMed	11
Andreessen Horowitz	11
MPM Capital	10
Artis Ventures	10
Sahsen Ventures	10
KdT Ventures	10
Rev1 Ventures	9
Longwood Fund	9
Versant Ventures	9
Lux Capital	9
Google Ventures	9
5AM Ventures	8
Cormorant Asset Management	8
Flagship Pioneering	8
Playground Global	8
Apple Tree Partners	8
iSelect Fund	8
New Enterprise Associates	8
Pear VC	8
The Column Group	8
Vivo Capital	8
SR One	8
Mission BioCapital	7
Dolby Family Ventures	7
Digitalis Ventures	7
Connecticut Innovations	7
Omega Funds	7
Foresite Capital	7
Horizons Ventures	7
Illumina Ventures	7
Breakout Ventures	7
Oreilly AlphaTech Ventures	7
Canaan Partners	6
First Round Capital	6
JDRF T1D Fund	6
Roche Venture Fund	6

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, China, United Kingdom

Portfolio highlights

Rhygaze — Rhygaze develops a novel gene therapy that targets cone cells to restore vision in patients suffering from diseases causing blindness.
Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
Atlas Data Storage — Atlas Data Storage develops data storage systems utilizing synthetic DNA to encode digital information. The company offers end-to-end solutions that integrate semiconductor-based synthesis and enzyme engineering to store data in DNA strands. This approach aims to provide long-term, high-density storage options for various sectors. Atlas DataStorage's technology is designed to address the growing demand for scalable and energy-efficient data storage solutions.

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

Investment focus

Biotechnology, Health Care, Software
Seed, Convertible Note, Pre-Seed
United States, India, United Kingdom

Portfolio highlights

MixRift — MIXRIFT - game developers specialized in Mixed Reality
unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.

Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that aredeveloping transformative new modalities and platforms to meaningfully improve human health.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Canada, France

Portfolio highlights

Remedy Plan Therapeutics — Remedy Plan is a biotechnology company developing the first drugs that halt tumor growth and disrupt the cancer stem cells that cause metastasis.
HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
GeneCentric Therapeutics — GeneCentric Therapeutics engages in developing and commercializing molecular diagnostic tests for oncologists and patients. The company currently has two unique platform technologies including The Lung Subtype Platform (LSP) stratifies lung cancer patients into subtypes, which are important for appropriate therapeutic selection. The firstapplication of LSP was licensed to and independently developed by Laboratory Corporation of America Holdings (“LabCorp”) and is now available through its specialty testing business, Integrated Oncology, as HistoPlusSM: Lung Cancer. Its second platform technology is the Hypoxia Signature which has the potential to identify patients that respond to anti-angiogenesis therapies.GeneCentric utilizes a unique partnership model to translate important cancer discoveries into clinically adopted diagnostics for pathologists, clinicians, and, most importantly, patients. The company was incorporated in 2011 and is based in Durham, North Carolina.

Northpond Ventures is a science-driven venture capital ﬁrm headquartered in Bethesda, Maryland. Our mission is to build a better tomorrow. Our investments are focused on life sciences, technology, and aﬃliated industries.

Investment focus

Biotechnology, Health Care, Life Science
Series A, Series B, Series C
United States, United Kingdom, Canada

Portfolio highlights

Vizgen — The next generation of genomics, expanding the impact of spatial context and demonstrating the potential of in situ single-cell spatial genomics.
VieCure — The VieCure platform is an Clinical Decision Support solution in Oncology that combines the power of artificial intelligence, codified clinical rules and pathways, precision oncology, telehealth, smartphone technology, and the EMR to transform cancer care.
Inflammatix — Inflammatix develops rapid point of care diagnostic tests by reading the immune system, and resolves major clinical health challenges.

RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series C, Post-IPO Equity
United States, United Kingdom, Canada

Portfolio highlights

Vor Biopharma — Shield the healthy cells, expose the cancer - Vor Bio (also known as Vor Biopharma) aims to cure blood cancers through cell and genome engineering.
Commons Clinic — Commons Clinic is a group of world class orthopedic surgeons in Los Angeles, CA. Our orthopedic specialists provide expert care from start to finish.
Spyglass Pharma — Spyglass Pharma focuses on the development of novel treatments for chronic ophthalmic diseases based on technology. The company designs to deliver multiple drugs to address additional ophthalmic indications.

Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Switzerland, United Kingdom

Portfolio highlights

Rhygaze — Rhygaze develops a novel gene therapy that targets cone cells to restore vision in patients suffering from diseases causing blindness.
Granite Bio — Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis. Granite Bio develops first-in-class therapeutic antibodies depleting pathogenic cells with the potential to transform inflammatory and fibrotic diseases.
Atalanta Therapeutics — Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases.

Third Rock Ventures invests in transformational life science companies that show high growth potential and are well-positioned to make a difference in the marketplace. Third Rock Ventures believes in the companies we start and makes significant initial investments, which are frequently supplemented by strategic collaborations, to help our firmsprogress in life-changing medicines, technologies, and diagnostics.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States

Portfolio highlights

Trace Neuroscience — Trace Neuroscience is a biopharmaceutical company that aims to extend the promise of genetic medicine to patients with neurodegenerative illnesses.
Candid Therapeutics — Candid Therapeutics is a biotechnology company that focuses on the treatment of a range of immunological conditions.
Seaport Therapeutics — Seaport Therapeutics operates as a clinical stage biopharmaceutical company.

Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on compelling opportunities to build scalable businesses and realize value.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, United Kingdom, Canada

Portfolio highlights

Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
Renasant Bio — Renasant Bio is a biopharmaceutical company pioneering disease-modifying oral small molecule treatments.
Vima Therapeutics — There are over 1 million people with dystonia and related movement disorders in the US and over 100,000 people with isolated dystonia.

8VC is a technology and life sciences investment firm that partners with founders to develop transformational technologies. The firm focuses on creating long-term economic and societal value through its investments across various sectors, including healthcare and logistics.

Investment focus

Software, Health Care, Artificial Intelligence
Series A, Seed, Series B
United States, United Kingdom, Canada

Portfolio highlights

Memebox — Memebox Corporation is a consumer company that provides customers with the Asian beauty products, culture, and trends. A global company focused on forecasting trends and creating private, in-house labels inspired by K-beauty (and made for the product obsessed).
Portal Biotech — Portal has created next generation solutions that address the significant opportunities in protein sequencing and metabolomics
Bedrock Robotics — Bedrock Robotics delivers enhanced autonomy to the built environment, allowing the construction sector to build at the rate that today's society requires.

We are deep tech venture capital.

Investment focus

Software, Artificial Intelligence, Health Care
Seed, Series A, Series B
United States, Canada, United Kingdom

Portfolio highlights

Eytrix — Eytrix enables governments and enterprises to query their security camera systems with ease, using natural language to search past footage (“Find a man with a blue backpack”), set up intelligent alerts (“Alert me if someone climbs over the wall”), and extract meaningful data from video streams (“How many vehicles entered yesterday?”)—all through aseamless, AI-powered interface.
Halter — Halter creates GPS enabled, solar powered collars for cows. The collar hardware allows farmers to use simple tablet app software to remotely set geographic boundaries for cattle, virtual fences. Farmers use Halter's system to avoid physically herding cows, maximizing farmer time and productivity.
Impulse Space — Economical and nimble last-mile space payload delivery

DIGITAL HEALTH / AI DIGITAL HEALTH / AI GENE / CELL THERAPIES NASDAQ: RCKT GENE / CELL THERAPIES NASDAQ: RCKT GENOMICS / DIAGNOSTICS GENOMICS / DIAGNOSTICS SYNTHETIC

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Series B
United States, United Kingdom, Brazil

Portfolio highlights

Antheia — Transforming pharmaceutical supply chains using synthetic biology, to end drug shortages and unlock new opportunities in development and discovery
SyntaxBio — SyntaxBio develops CRISPR/Cas9-based, genetic programming platform that converts cells into biological computers using DNA-based instructions that read like lines of code. SyntaxBio's platform can program cells without the need for consistent external intervention.
Integrated Biosciences — Integrated Biosciences is the first company in history to be able to virtually stress cells.

Supporting early stage Life Science startups driving patient impact. Born from our collective experience as founders, we set out to build the fund we wanted to raise from....

Investment focus

Health Care, Biotechnology, Life Science
Series A, Seed, Pre-Seed
United States

Portfolio highlights

Elegen — Skip cloning with NGS-verified, cell-free DNA up to 7 kb. Error rates as low as 1:70,000/bp. Manufactured in USA, shipped globally in 6 to 8 business days. .
Zafrens — Zafrens specializes in developing tools and generating insights at the interface of biology, chemistry, and engineering. The company was founded in 2021 and is headquartered in San Diego, California, United States.
Galatea Bio — Galatea Bio, a US-based biotechnology company was founder by Carlos Bustamante, Nicholas Katsanis and Alexander Ioannidis. Our mission is to drive groundbreaking discoveries in healthcare by pairing genetic diversity with cutting-edge data analytics. Our passion is fueled by a focus on populations historically underrepresented in genetics research.We achieve this by leveraging our world-class clinical network and biobank, cutting-edge algorithms, and innovative analyses to discover and validate new tests, treatments, and cures that will improve the lives of all.

WE BACK HEROES using technology to solve the world's biggest problems

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Series B
United States, Germany, Canada

Portfolio highlights

Deepcell — Deepcell uses AI to isolate and capture cells based on morphological features for multiple research and translational applications.
Gridware — Using remote telemetry and edge AI, Gridware wildfire prevention technology powers a grid that is smarter and more reliable than ever before.
Aalo Atomics — Creating abundant and dependable clean energy to power humanity for generations.

Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to buildingsuccessful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Canada

Portfolio highlights

410 Medical — 410 Medical has developed a simple, intuitive solution that allows a single healthcare provider to rapidly deliver fluid to critically ill patients, improving care, and saving lives. Their device allows fast set-up, improves resuscitation speed, minimizes provider fatigue, and frees providers to address other patient care issues simultaneously.This solution is particularly useful in pre-hospital settings and the emergency department and where speed is critical and resources may be limited.It was founded in 2013 and headquartered in Durham, North Carolina.
Atsena Therapeutics — Atsena is a clinical-stage gene therapy company, focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness.
GeneCentric Therapeutics — GeneCentric Therapeutics engages in developing and commercializing molecular diagnostic tests for oncologists and patients. The company currently has two unique platform technologies including The Lung Subtype Platform (LSP) stratifies lung cancer patients into subtypes, which are important for appropriate therapeutic selection. The firstapplication of LSP was licensed to and independently developed by Laboratory Corporation of America Holdings (“LabCorp”) and is now available through its specialty testing business, Integrated Oncology, as HistoPlusSM: Lung Cancer. Its second platform technology is the Hypoxia Signature which has the potential to identify patients that respond to anti-angiogenesis therapies.GeneCentric utilizes a unique partnership model to translate important cancer discoveries into clinically adopted diagnostics for pathologists, clinicians, and, most importantly, patients. The company was incorporated in 2011 and is based in Durham, North Carolina.

Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, China, Israel

Portfolio highlights

Renasant Bio — Renasant Bio is a biopharmaceutical company pioneering disease-modifying oral small molecule treatments.
Alpheus Medical — Our Brain Cancer Clinical Trial is investigating Sonodynamic Therapy. A painless, non-invasive ultrasonic technology for the treatment of glioblastoma.
CytomX Therapeutics — CytomX Therapeutics is a biotechnology company that focuses on developing proteolytically-activated antibodies. Their mission, alone and with the help of partners, is to provide patients with more effective and less toxic therapies for severe illnesses such as cancer and inflammatory diseases.

Andreessen Horowitz (a16z) is a venture capital firm in Silicon Valley, California, investing in bold founders, innovators, and entrepreneurs building the future through technology.

Investment focus

Software, Information Technology, Internet
Series A, Seed, Series B
United States, United Kingdom, Brazil

Portfolio highlights

OpenRouter — OpenRouter is a platform that connects AI applications with large language models and cloud hosting providers, allowing users to optimize for costs, speed, and performance. The platform supports over 180 AI models, offers a unified API, and includes functionalities like private chat and exploratory data capabilities. OpenRouter sets the newbenchmark for large-scale AI inference with its global edge infrastructure, privacy-focused design, real-time accounting, and integrated billing.
Shield USDT — Shield is the first B2B cryptocurrency exchange designed for international businesses. Access a US-based virtual bank account to buy, sell, and transfer crypto.
Abridge — For patients, clinicians, and enterprise, our audio-based solutions capture the details and summarize medical conversations, anywhere care happens.

Powering Breakthroughs in Life Sciences

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series A, Series B, Series C
United States, Canada, United Kingdom

Portfolio highlights

āshibio — āshibio creates treatments for rare bone and connective tissue ailments, potentially preventing symptoms or slowing their course.
Umoja Biopharma — Pioneering immunotherapy by reprogramming T cells in vivo to target cancer cells.
Reunion Neuroscience — Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depressionand other mental health conditions. Reunion is also developing the RE200 series, which includes compounds with the potential for more selective serotonin receptor activity and reduced psychoactivity for application in more chronic treatment paradigms and indications.

Artis Ventures has spent over a decade backing bold teams who take the hard path, building market-defining companies to re-shape, re-invent, and re-make industries.

Investment focus

Health Care, Biotechnology, Software
Series A, Series B, Seed
United States, India, Germany

Portfolio highlights

Network Bio — Network Bio is a clinical and molecular data library enabling precision medicine approaches for common human diseases. Its platform delivers a centralized repository for clinical and molecular data that allows researchers to identify patterns and correlations that can be used to develop new treatments and diagnostic tools.
Outpace Bio — Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
Second Front Systems — The continuous accreditation and deployment of commercial software is crucial for U.S. national security missions. With Second Front Systems' Game Warden platform, you'll be achieving exactly that.

Sahsen Ventures is a venture capital firm making investments in for-profit and nonprofit organizations with an emphasis on technology and biotechnology. It was established in 2016 and is based in Seattle, Washington.

Investment focus

Biotechnology, Health Care, Non Profit
Funding Round, Series A, Seed
United States, China, Ghana

Portfolio highlights

Insamo — Insamo is a global biotechnology company pioneering the discovery of membrane-permeable and orally available cyclic-peptides with antibody-like binding affinity.
Outpace Bio — Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
Archon Biosciences — Archon is a biotechnology firm that creates computationally engineered proteins to unleash potent therapeutic targets beyond the grasp of current methods and improve disease management.

KdT Ventures is the standard for early-stage frontier science investing.

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Series B
United States, Israel, Germany

Portfolio highlights

Shiprocket — Shiprocket is India's most-used eCommerce logistics and shipping software solution for the best courier services. Avail features like COD (Cash on Delivery), prepaid delivery, automated shipping, etc.
March Biosciences — Transforming Patient Care by Unlocking New Target Spaces March Biosciences is a clinical-stage company in the cell therapy field focused on developing CAR-T cell strategies to address the most challenging hematological cancers Pipeline MB-105 https://march.bio/wp-content/uploads/2023/05/shutterstock_1008023995-HD-30.mp4 Focused on Excellence Target Space Our approach combines biological and engineering insights to enable target-unlock without the risk and complexity
Montara Therapeutics — Montara Therapeutics is a precision-medicine neuroscience biotech startup improving safety and efficacy of therapies for people with neurological diseases

Rev1 Ventures provides seed stage venture capital funding in Columbus, Ohio along with startup services, space, mentoring, and connections. Learn more!

Investment focus

Software, Health Care, Information Technology
Seed, Series A, Funding Round
United States, Germany

Portfolio highlights

Myoptechs — Myoptechs, a pediatric ophthalmic medical device startup in the clinical stage, has made advancements in its fund-raising and clinical research program. The company creates innovative soft contact lenses and spectacles that reduce the growth of myopia while offering incredibly clear vision.
Nichefire — Nichefire is an AI-power marketing analytics company.
STAQ Pharma — STAQ Pharma is an FDA-registered 503B outsourcing partner that provides critical medications for pediatric and adult patients across the country. As a hospital-backed and directed pharmaceutical outsourcing partner, STAQ Pharma is positioned to strengthen the supply chain for drug shortages, understand provider needs, and ensure safety in critical medications.

Longwood creates and invests in science-based companies that develop novel solutions for important medical problems

Investment focus

Biotechnology, Therapeutics, Health Care
Series A, Series B, Series C
United States, United Kingdom, Italy

Portfolio highlights

Evommune — Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.
Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
Newleos Therapeutics — Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines.

Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Switzerland, Canada

Portfolio highlights

Granite Bio — Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis. Granite Bio develops first-in-class therapeutic antibodies depleting pathogenic cells with the potential to transform inflammatory and fibrotic diseases.
Helicore Biopharma — Helicore Biopharma is at the forefront of developing cutting-edge treatments for obesity and related disorders.
Light Horse Therapeutics — Light Horse Therapeutics is the gene editing applied to small-molecule drug discovery, pioneering approaches to target the root causes of disabling and life-threatening diseases. Its advanced platform identifies cryptic chemically accessible functional domains within targets that are critical in disease biology. Our initial focus addresseshigh-value, historically challenging oncology targets with the opportunity to apply the technology to other therapeutic areas in the future.

Lux Capital manages over $5 billion in assets focused on founding, seed, early-stage, and growth investments at the intersection of technology and the sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high-growth sectors. Its investment team has built over 20 companies from scratch. Lux's investmentstrategy ensures portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.

Investment focus

Software, Health Care, Artificial Intelligence
Series A, Seed, Series B
United States, United Kingdom, Canada

Portfolio highlights

Armada — The Armada Platform is a whole new way to succeed at the Edge with Starlink connectivity, mobile data centers & AI. Schedule a demo today.
Varda — Expanding the economic bounds of humankind with the world's first orbital manufacturing & reentry platform.
Hadrian — We are building the planet's most efficient factory to accelerate a democratic, abundant, spacefaring future.

GV supports innovative founders moving the world forward.

Investment focus

Software, Health Care, Biotechnology
Series A, Series B, Seed
United States, United Kingdom, Switzerland

Portfolio highlights

PostHog — PostHog is the only all-in-one platform for product analytics, feature flags, session replays, experiments, and surveys that's built for developers.
OpenEvidence — OpenEvidence uses artificial intelligence to aggregate, synthesize, and visualize clinical evidence in understandable, clinically-useful formats that can be used to make more evidenced-based decisions and improve patient outcomes.
Glass Imaging — Traditional cameras rely on an imaging lens which typically consists of several lens elements and a light sensitive sensor. Cameras have been built like this since 1816. Glass has been historically used to make high quality optical elements. We are replacing these elements with deep neural networks that give extreme flexibility when designing ourcameras. It allows us to squeeze a huge sensor into an ultra thin module that fits perfectly into a mobile device without the need for protruding bumps. Our cameras bring SLR image quality into your pocket.

5AM Ventures is a venture capital firm that offers seed- and early-stage investments to its clients. The company’s client portfolio consists of firms in the biopharmaceutical, life sciences, medical technology, and research instrument industries. 5AM Ventures was founded in 2002 by John Diekman and Andrew Schwab and is based in California.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Switzerland, United Kingdom

Portfolio highlights

Surrozen — Surrozen is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Surrozen is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with potential application across multiple disease areas, including diseases of the intestine, liver, retina,cornea, lung, kidney, cochlea, skin, pancreas and central nervous system.
Renasant Bio — Renasant Bio is a biopharmaceutical company pioneering disease-modifying oral small molecule treatments.
Latigo Biotherapeutics — Operator of a drug discovery company intended to develop novel, non-opioid therapies for chronic pain. The company utilizes unique, translated insights to provide a differentiated approach to targeting therapeutics across the blood-nerve barrier, enabling patients to get access to a pain management therapy that does not create addiction, dependenceor tolerability.

Cormorant Asset Management is an employee-owned hedge fund sponsor that provides its services to pooled investment vehicles. The firm also focuses on both public and private market innovative companies in the biotechnology and life sciences marketplace.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, China, Switzerland

Portfolio highlights

Numab — Numab Therapeutics AG
Neurona Therapeutics — Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs.
Edgewise Therapeutics — See how we bring our unique expertise and singular focus on muscle science to develop novel therapeutics for serious skeletal and cardiac muscle diseases.

We create breakthroughs in human health and sustainability and build bioplatform companies . Companies founded

Investment focus

Biotechnology, Health Care, Medical
Series B, Series C, Series A
United States, Canada, United Kingdom

Portfolio highlights

Etiome — Etiome is disrupting the progression of disease before it becomes debilitating and irreversible by developing and deploying Biostaged Medicines.
Terrana Biosciences — Terrana's innovative technological platform enables resilient agriculture in a fast changing world by providing RNA-based plant health solutions.
Ampersand Biomedicines — Ampersand is enabling potent mechanisms to treat disease by creating and programming therapeutics that are more efficacious, without compromising on safety or tolerability.

Playground Global is an early-stage venture capital firm backing technical and scientific founders with deep engineering expertise, a collaborative environment, and a first-hand understanding of the intricacies of deep tech. Established in 2015 and headquartered in Palo Alto, CA, Playground’s mission is to transform ambitious ideas into impactfulbusinesses that benefit humanity and the planet. We invest in areas that span across next gen compute automation, energy transition and engineered biology. Playground has been an early – and frequently first investor – in companies that include PsiQuantum, Relativity Space, Ultima Genomics, MosaicML (acq. by Databricks), d-Matrix, and Strand Therapeutics.

Investment focus

Software, Robotics, Biotechnology
Series A, Seed, Series B
United States, Canada, France

Portfolio highlights

Aerones — Robotic wind turbine service company offering maintenance, inspection and repairs worldwide. Reduce downtime and improve the efficiency of your wind park
Snowcap Compute — Snowcap Compute develops advanced artificial intelligence computing chips that leverage superconducting technology for faster processing and greater energy efficiency.
Synthetic Design Lab — The Synthetic Design Lab platform is engineered to optimize targeted payload delivery ≥10x compared to current ADCs, potentially improving upon the efficacy, safety, and overall versatility of earlier ADCs.

ATP, a global leader in life sciences venture capital, is developing the next generation of transformative biotechnology companies. ATP creates science-based companies starting with assets at various stages: from working with scientists on pre-IP ideas, to spinouts from existing company pipelines. The firm provides flexible capital, strategicinsight, and operational resources to build sustainable, research-driven enterprises. ATP invests in its portfolio companies from seed stage through IPO and beyond and supports their management teams in strategic transactions and synergistic business combinations.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Canada, United Kingdom

Portfolio highlights

Ascidian Therapeutics — Ascidian Therapeutics is a biotechnology company developing exon-editing RNA therapeutics to target the underlying causes of disease.
Red Queen Therapeutics — Staying ahead of viral threats with new innovations in antiviral therapy
Deep Apple Therapeutics — Deep Apple Therapeutics is discovering new small-molecule therapeutics with unprecedented speed and exceptional acumen.

Venture investing in Food, Health, and AgTech. A generational investment thesis. Food is Health is longevity

Investment focus

Biotechnology, Health Care, Software
Seed, Series A, Funding Round
United States, Australia, New Zealand

Portfolio highlights

BioLumic — BioLumic develops light signals that activate plant growth and unlock the natural genetic potential of crops. The company's photogenics platform leverages innovation in plant science, light technology and genetic insights. Demonstrated results include higher yield, improved vigor, increased disease and pest resistance, and improvements incrops composition. These results have been across a variety of seeds and seedling: soybean, cannabis and vegetable and fruit crops. It is a clean technology that does not require the use of chemicals or amendments. BioLumic is a private company and was founded in 2013.
Edacious — Edacious is a new food system. Our company can help you differentiate the quality of your food.
Growers Edge — Growers Edge leverages data science to build grower-relevant risk management solutions to meet ever-changing agricultural demands.

Foundational partners to ambitious founders at every stage of company-building.

Investment focus

Software, Health Care, Biotechnology
Series A, Series B, Series C
United States, India, Canada

Portfolio highlights

NG.CASH — NG.CASH is a digital app designed to help Generation Z become financially independent. It allows users to manage their own money with solutions such as PIX (Brazil’s “instant-payment” method), prepaid credit card, allowance management and a virtual card, in addition to features that let users customise the app’s design and a marketplace withdiscounts on Gen Z’s most desired brands. Structured as a financial hub, NG.CASH aims to accompany its clients throughout their lives and increase financial literacy in the region.
Wispr Flow — Wispr AI is a developer of the next-generation of neural interfaces to provide seamless interface with immersive technology. The company is working with the leading neuroscientist, hardware engineers, machine learning researchers, and product engineers to bring frontier technology to the mass consumer market.
Spyglass Pharma — Spyglass Pharma focuses on the development of novel treatments for chronic ophthalmic diseases based on technology. The company designs to deliver multiple drugs to address additional ophthalmic indications.

Pear VC partners with entrepreneurs from day zero to build category-defining companies.

Investment focus

Software, Artificial Intelligence, Health Care
Seed, Series A, Pre-Seed
United States, Brazil, Colombia

Portfolio highlights

Memebox — Memebox Corporation is a consumer company that provides customers with the Asian beauty products, culture, and trends. A global company focused on forecasting trends and creating private, in-house labels inspired by K-beauty (and made for the product obsessed).
Axle Health — Axle Health provides scheduling and workforce management software to help home healthcare and hospice providers improve their clinician productivity.
Piston — The Smarter Way to Fuel Your Fleet

The Column Group (TCG) is a venture ecosystem dedicated to fueling scientific innovation in the life sciences industry.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States

Portfolio highlights

A2 Biotherapeutics — A2 is dedicated to advancing cancer treatment through pioneering cell therapy. Our T cells target solid tumors with precision, transforming the future of medicine.
Eikon Therapeutics — Eikon Therapeutics is a drug discovery and development company that leverages super-resolution microscopy as well as the latest advances in biology, chemistry, engineering, and automation toward the goal of discovering and inventing innovative therapies that will improve and extend life.
Neurona Therapeutics — Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs.

The firm is a 25-year-old global investment firm focused on healthcare with approximately $5.8 billion in AUM, which we have invested in over 290 public and private companies worldwide. Headquartered in Palo Alto, California, with offices in Asia. Our team consists of 50 multi-disciplinary professionals, including, physicians, scientists,entrepreneurs, operating executives, and industry experts. The firm operates as a multi-fund investment platform, covering growth equity, private equity including buyout, venture capital, and public equity. Vivo invests broadly in healthcare across all fund strategies, including biotechnology, pharmaceuticals, medical devices, and healthcare services, with a focus on the largest healthcare markets.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series B, Series C, Post-IPO Equity
United States, China, United Kingdom

Portfolio highlights

35Pharma — 35Pharma is a biopharmaceutical company that designs and develops innovative biologics for diseases of high unmet medical need.
Trevi Therapeutics — Trevi Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Trevi is currently developing nalbuphine ER for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF), andlevodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. These conditions share common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Trevi is currently conducting a Phase 2b/3 clinical trial of nalbuphine ER, referred to as the PRISM trial, in patients with severe pruritus associated with prurigo nodularis.
Chentai New Materials — Chentai New Materials integrates the R&D, design, manufacturing, and sales of high-performance composite ceramics. It Specializes in the innovation and creation of medical high-performance ceramic products.

SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, United Kingdom, Canada

Portfolio highlights

Fore Biotherapeutics — We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics.
Draig Therapeutics — Draig Therapeutics is a clinical-stage biopharmaceutical startup dedicated to creating next-generation treatments for serious neuropsychiatric illnesses.
ORIC Pharmaceuticals — ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s lead product candidate,ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeuticsacross a variety of solid tumors. ORIC’s second product candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens. Beyond these two product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC’s scientific founders, Charles Sawyers, MD, and Scott Lowe, PhD, have long records of discovering novel targets in cancer that have led to innovative treatments.

Mission BioCapital is a life science venture capital firm that invests in early-stage companies. The company leadership team has a long history together, investing in and launching dozens of early-stage life science companies. They are located in regions with a rich concentration of research, discovery, and venture capital investment, and they areknown by leaders of portfolio companies for the expertise and deep support they provide.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Funding Round, Series B
United States, Germany, Switzerland

Portfolio highlights

D2B3 — The future of treating brain diseases.
Alessa Therapeutics — Alessa Therapeutics is a pre-clinical stage company that develops localized treatments for solid organ disease.
SiteOne Therapeutics — SiteOne develops selective inhibitors of sodium channels as non-opioid treatments to address acute and chronic pain

Investing in early-stage companies solving the biggest science and engineering challenges since 2014.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Seed, Series B
United States, Austria, Switzerland

Portfolio highlights

NeuroBionics — NeuroBionics aims to advance neurotech and human health through bioelectronic medicine, by developing devices that seamlessly integrate with the human body.
Montara Therapeutics — Montara Therapeutics is a precision-medicine neuroscience biotech startup improving safety and efficacy of therapies for people with neurological diseases
Esper Satellite Imagery — Esper is building and launching the world's most versatile satellite imagery network for mineral exploration, agronomy, and national security. Order imagery now.

Engineering solutions to complex problems in health through venture investment and company creation.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Seed
United States, United Kingdom, China

Portfolio highlights

Galatea Bio — Galatea Bio, a US-based biotechnology company was founder by Carlos Bustamante, Nicholas Katsanis and Alexander Ioannidis. Our mission is to drive groundbreaking discoveries in healthcare by pairing genetic diversity with cutting-edge data analytics. Our passion is fueled by a focus on populations historically underrepresented in genetics research.We achieve this by leveraging our world-class clinical network and biobank, cutting-edge algorithms, and innovative analyses to discover and validate new tests, treatments, and cures that will improve the lives of all.
Gallant — Gallant Pet is a pet service company that develops a stem cell therapy intended for dog wounds.The company offers services that include retrieving valuable stem and regenerative cells, enabling pet owners to preserve their pet's young stem, and use them in treatment when necessary.Gallant Pet was established in 2018 by Aaron Hirschhorn andis headquartered in San Diego, California.
Gallant Therapeutics — Gallant Therapeutics is an animal health biotechnology company developing allogeneic, "off-the-shelf" stem cell therapies from their stem cell platform. Gallant is also the leading provider of non-invasive stem cell banking during the spay or neuter process, opening the door to novel regenerative medical treatments formerly unavailablefor non-human family members. Clinical studies demonstrate stem cell therapies help pets with a multitude of ailments, including osteoarthritis, atopic dermatitis, chronic kidney disease, and chronic stomatitis, among others. Gallant's first product helps to save cats that would die of chronic gingivostomatitis, with a robust pipeline in development for companion animals.

At Connecticut Innovations, we see venture capital the way you see your business. Like no one else. We invest in innovative biotech, IT, and other industries.

Investment focus

Health Care, Biotechnology, Software
Seed, Series A, Funding Round
United States, Israel, Canada

Portfolio highlights

Normunity — We create medicines that free normal immunity to defeat cancer using proprietary platforms that uncover novel immuno-oncology mechanisms.
VeraDermics — VeraDermics Inc. is a dermatology pharmaceutical start-up, makers of WartPatch
PHȲND — PHȲND is a subscription-free cloud gaming platform that offers a way to discover, play, and socialize across a wide variety of games.

We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Switzerland, United Kingdom

Portfolio highlights

Windward Bio — Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programsfor various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field.
Alleviant Medical — Interventional therapy for congestive heart failure
Callio Therapeutics — Callio Therapeutics focuses on developing next-generation, multi-payload antibody-drug conjugates to maximize therapeutic benefits.

We are a multi-stage investment firm, investing in companies that leverage biology and big data to transform healthcare.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series C, Series A
United States, United Kingdom, Australia

Portfolio highlights

RayThera — RayThera specializes in developing breakthrough small molecule therapies for critical unmet needs in immunology. Backed by decades of drug discovery expertise, we accelerate the development process while maintaining rigorous standards.
Eikon Therapeutics — Eikon Therapeutics is a drug discovery and development company that leverages super-resolution microscopy as well as the latest advances in biology, chemistry, engineering, and automation toward the goal of discovering and inventing innovative therapies that will improve and extend life.
Latigo Biotherapeutics — Operator of a drug discovery company intended to develop novel, non-opioid therapies for chronic pain. The company utilizes unique, translated insights to provide a differentiated approach to targeting therapeutics across the blood-nerve barrier, enabling patients to get access to a pain management therapy that does not create addiction, dependenceor tolerability.

Investing in the deep science and technology that can propel humanity towards a radically better future.

Investment focus

Biotechnology, Artificial Intelligence, Software
Series A, Series B, Seed
United States, United Kingdom, Canada

Portfolio highlights

Notpla — We are a combination of designers and chemists, engineers and entrepreneurs. We’re hard to define because what we’re doing hasn’t been done before. We create advanced packaging solutions that disappear, naturally.
Owlstone Medical — Owlstone Medical has developed a breathalyzer for disease. With a focus on non-invasive diagnostics for cancer, inflammatory disease, and infectious disease, the company aims to save 100,000 lives and $1.5B in healthcare costs.The company’s Breath Biopsy® platform has introduced a new diagnostic modality making it possible to discover novelnon-invasive biomarkers in breath using a platform with the potential to transition to point-of-care. The award-winning ReCIVA Breath Sampler ensures a reliable collection of breath samples. The volatile organic compounds (VOCs) present in the breath are analyzed using proven microchip chemical sensor technology (FAIMS) to detect biomarkers of disease.The Breath Biopsy platform can be used in clinical diagnostics and precision medicine with applications in cancer and a wide range of other medical conditions. Highly sensitive and selective, these tests allow for early diagnosis when treatments are more effective and more lives can be saved.Owlstone Medical is currently developing tests for lung and colorectal cancer, two of the most common cancer killers worldwide, and for asthma stratification by the therapeutic response. The company also Breath Biopsy products and services to academic, clinical, and pharma partners who want to develop breath-based diagnostics for their own applications.
Fleet Space Technologies — Fleet is an agile, next generation connectivity company. Our mission is to Connect Everything using cutting-edge communications and space technologies to maximise the resource efficiency of human civilisation and enable the next industrial revolution with our free, ubiquitous connectivity platform.

We invest in companies that are advancing the field of genomics and pioneering new applications in healthcare, agriculture, environmental science, and personal

Investment focus

Biotechnology, Health Care, Life Science
Series A, Series B, Series C
United States, United Kingdom, France

Portfolio highlights

Arima Genomics — Use the most advanced Hi-C technology to power your discoveries with unparalleled access to the sequence + structure of any genome.
Infinity Bio — Infinity Bio is a biotech company that offers analytics and insight services for antibody reactome profiling against all human viruses.
Attovia Therapeutics — Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients in being treated.

Breakout Ventures is a new, early stage fund that backs bold scientist entrepreneurs working at the intersections of technology, biology, materials, and energy.

Investment focus

Biotechnology, Life Science, Therapeutics
Seed, Series B, Series A
United States

Portfolio highlights

CytoVale — Cyotvale offers IntelliSep, an FDA-cleared early sepsis detection test powered by the Cytovale System medical device.
Passkey — Passkey Therapeutics is pioneering a new class of medicines, Synergistic Multifunctional Therapeutics (SMThs). It is designed to address complex diseases by targeting rare combinations of proteins that work together.
Copernic Catalysts — Mantel is developing the material solution to carbon capture

O'Reilly AlphaTech Ventures (OATV) is in the business of funding disruptors, innovators, and hackers of the status quo. From open source to the early days of the web and its recent resurgence, O'Reilly Media has played a key role as trend spotter and advocate for putting world-changing technologies on the map. OATV effort is to bring thelegacy, resources, and relationships of O'Reilly to each investment they make.

Investment focus

Software, E-Commerce, Analytics
Series A, Seed, Series B
United States, United Kingdom, Canada

Portfolio highlights

Pachama — Harnessing AI to drive carbon capture and protect global forests
Paintbrush — Paintbrush provides access to funding for idea-stage founders who are too early for other options.
Impart Security — Real-time API Security spanning discovery, monitoring, and enforcement.

Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $5B under management, a diversified fund and over 190 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 30 years. Canaan’s focus areas include fintech, enterprise/cloud,marketplaces, frontier tech, biopharma, digital health, and medtech.

Investment focus

Software, Biotechnology, Health Care
Series A, Series B, Series C
United States, United Kingdom, Israel

Portfolio highlights

Glooko — Glooko's digital health and connected care solutions improve health outcomes for people with diabetes and related chronic conditions.
Nivoda — Nivoda provides jewellery businesses with a simple solution to strengthen profits, increase efficiency and accelerate growth with its B2B diamond marketplace. Designed to save you time and money whilst giving you access to the world’s diamond supply at the best prices with zero inventory risk, Nivoda is trusted by thousands of retailers all overthe globe.
Enterpret — All customer feedback categorized automatically, combined with advanced analytics capabilities that ensure no customer pain goes unnoticed.

First Round is a seed-stage venture firm focused on building a vibrant community of technology entrepreneurs and companies.

Investment focus

Software, Information Technology, E-Commerce
Seed, Series A, Series B
United States, Canada, India

Portfolio highlights

Andrenam — Andrenam is building an AI-powered, distributed maritime sensing network for persistent autonomous awareness from surface to seabed.
Solidroad — Increase CSAT without increasing cost with the AI QA & training platform that reviews 100% of your customer conversations. Generate individualized training simulations for human reps and refinement recommendations for AI agents.
arketa — Online and in-person classes, video on-demand, courses and website hosting - all in one platform with arketa.

The JDRF T1D Fund (www.t1dfund.org) is a venture philanthropy fund exclusively devoted to finding and funding the best early-stage T1D commercial opportunities to accelerate the delivery of treatments, preventions, and cures to patients. It was created to solve a critical funding gap in the T1D drug and device development pipeline. Throughpartnerships with private capital, including venture capital, pharma and foundations, the T1D Fund anticipates that it will be able to attract substantially more private investment to the T1D field than occurs today. The T1D Fund will initially focus on artificial pancreas systems, metabolic control, beta cell replacement, prevention, and beta cell restoration therapies, with an exclusive priority on the best commercial opportunities. The T1D Fund will reinvest any realized gains into new investments to further its mission.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Funding Round, Series B
United States, France, Italy

Portfolio highlights

vTv Therapeutics — vTv Therapeutics, a pharmaceutical company, focuses on the discovery and development of human therapeutics to fill unmet medical needs. Its mission is to utilize its innovative technology to rapidly translate the functional modulation of human proteins into safe and effective medicines.vTv Therapeutics has a pipeline of small molecule clinicaland pre-clinical drug candidates for the treatment of a wide range of human diseases including central nervous system disorders, metabolic disorders, inflammation, and cancer. The company has built its product candidate portfolio through internal discovery and is advancing its product candidates through in-house research and development efforts. The quality and breadth of vTv's product candidate pipeline, platform technology, scientific team, and strategic collaborations have enabled it to become a fully integrated pharmaceutical company.The company's commitment to drug discovery is reflected in its medical solutions and the many exciting potential new treatment options in its pipeline. The company's major R&D activities have focused on central nervous system disorders, metabolic disorders, inflammation and oncology.vTv Therapeutics is advancing several proprietary drug candidates. The company's lead candidate, azeliragon (aka TTP488), is a novel, orally bioavailable small molecule compound that is being developed for the treatment of Alzheimer's disease. In Phase 2 clinical trial in patients with mild to moderate Alzheimer's disease, azeliragon showed a statistically significant difference of more than 3 points in ADAS-cog at 18 months compared to placebo.Azeliragon has been granted Fast Track Designation and agreement on its Phase 3 protocol has been reached with FDA via a Special Protocol Assessment (SPA). The Phase 3 study in patients with mild Alzheimer's disease was initiated in April 2015 with a clear path forward to registration with the aim to demonstrate disease modification.vTv Therapeutics is also prosecuting the clinical development of TTP399, a novel functionally liver-selective Glucokinase Activator ("GKA") for the treatment of type 2 diabetes. In a Phase 2a study, TTP399 normalized patients' HbA1c without inducing hypoglycemia, after only six weeks of treatment. A six-month Phase 2 study is ongoing.
Eledon Pharmaceuticals — Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease.
Cour Pharmaceuticals Development — COUR Pharmaceuticals is developing first-in-class therapies designed to reprogram the immune system to achieve antigen-specific tolerance...

We are the corporate venture fund of Roche, a global leader in bringing medicines and in vitro diagnostics to the benefit of patients.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, United Kingdom, Spain

Portfolio highlights

DiogenX — Welcome to DiogenX. Explore our pioneering research and innovative therapies aimed at transforming diabetes treatment
Mironid — Google Analytics is a web analysis service provided by Google. Google utilizes the data collected to track and examine the use of www.mironid.com, to prepare reports on its activities and share them with other Google services. Google may use the data collected to contextualize and personalize the ads of its own advertising network.
MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas

Investors by industry